Home » Stocks » CLLS

Cellectis S.A. (CLLS)

Stock Price: $22.69 USD 1.19 (5.53%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
After-hours: $22.60 -0.09 (-0.40%) Mar 1, 7:03 PM
Market Cap 995.29M
Revenue (ttm) 86.78M
Net Income (ttm) -94.04M
Shares Out 42.47M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $22.69
Previous Close $21.50
Change ($) 1.19
Change (%) 5.53%
Day's Open 21.81
Day's Range 21.82 - 23.17
Day's Volume 226,712
52-Week Range 7.32 - 34.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 week ago

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells (iPSC)...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) a...

GlobeNewsWire - 2 weeks ago

(Article 223-16 of General Regulation of the French financial markets authority)

InvestorPlace - 1 month ago

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared f...

Other stocks mentioned: BEAM, CLXT, CRSP, EDIT, NTLA, SGMO
GlobeNewsWire - 1 month ago

(Article 223-16 of General Regulation of the French financial markets authority)

Zacks Investment Research - 2 months ago

Cellectis (CLLS) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-ed...

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing...

GlobeNewsWire - 2 months ago

(Article 223-16 of General Regulation of the French financial markets authority)

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-ed...

Seeking Alpha - 3 months ago

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-...

Other stocks mentioned: ALLO, ATRA, BMY, CRSP, GILD, NVS, PFE
GlobeNewsWire - 3 months ago

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic...

GlobeNewsWire - 3 months ago

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-ed...

GlobeNewsWire - 3 months ago

(Article 223-16 of General Regulation of the French financial markets authority)

Seeking Alpha - 3 months ago

Cellectis' (CLLS) CEO André Choulika on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogen...

GlobeNewsWire - 3 months ago

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-ed...

GlobeNewsWire - 4 months ago

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edi...

Zacks Investment Research - 4 months ago

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Other stocks mentioned: EBS, TMO, VRTX
GlobeNewsWire - 5 months ago

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on ge...

Seeking Alpha - 6 months ago

Cellectis S.A. (CLLS) CEO André Choulika on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allog...

GlobeNewsWire - 7 months ago

NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene...

The Motley Fool - 7 months ago

Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.

Other stocks mentioned: ALLO, GILD, NVS, TCRR
GlobeNewsWire - 7 months ago

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene...

GlobeNewsWire - 7 months ago

Dr. Yves Ribeill, Member of Calyxt’s Board of Directors since 2018, Appointed Chairman of the Board; Laurent Arthaud named Director, designated by Cellectis Dr. Yves Ribeill, Member of Calyxt’...

GlobeNewsWire - 7 months ago

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited alloge...

Zacks Investment Research - 8 months ago

Is (CLLS) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 8 months ago

NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 29, 2020 at its head office in Pari...

Seeking Alpha - 8 months ago

Cellectis has shown promise in its oncology treatment and a new paper shows that it's able to overcome early risk detection.

GlobeNewsWire - 8 months ago

NEW YORK, June 25, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogen...

Zacks Investment Research - 8 months ago

Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Cellectis.

GlobeNewsWire - 9 months ago

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-...

Zacks Investment Research - 9 months ago

Cellectis (CLLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 9 months ago

(Article 223-16 of General Regulation of the French financial markets authority)

Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for May 12th

Other stocks mentioned: CHGG, HEAR, ISEE
Seeking Alpha - 9 months ago

Cellectis' (CLLS) CEO André Choulika on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

Industry veteran joins Cellectis leadership team as UCART product pipeline advances in clinical trials Industry veteran joins Cellectis leadership team as UCART product pipeline advances in cl...

GlobeNewsWire - 10 months ago

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)

Zacks Investment Research - 10 months ago

Cellectis S.A. (CLLS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 11 months ago

Cellectis has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Seeking Alpha - 11 months ago

Cellectis SA (CLLS) CEO André Choulika on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Cellectis S.A. (CLLS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Seeking Alpha - 1 year ago

Time To Slowly Scale In To Cellectis

The Motley Fool - 1 year ago

Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.

Other stocks mentioned: DTIL, CLXT
Zacks Investment Research - 1 year ago

With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

Other stocks mentioned: ALXN, AMRN
The Motley Fool - 1 year ago

The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.

About CLLS

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 7, 2007
CEO
Andre Choulika
Employees
253
Stock Exchange
NASDAQ
Ticker Symbol
CLLS
Full Company Profile

Financial Performance

In 2019, Cellectis's revenue was 22.99 million, an increase of 7.27% compared to the previous year's 21.43 million. Losses were -102.09 million, 29.7% more than in 2018.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Cellectis stock is "Buy." The 12-month stock price forecast is 35.10, which is an increase of 54.69% from the latest price.

Price Target
$35.10
(54.69% upside)
Analyst Consensus: Buy